Novel inhibitors of AKT: Assessment of a different approach targeting the pleckstrin homology domain

Current Medicinal Chemistry

Volumn 18, Issue 18, 2011, Pages 2727-2742

  Meuillet, E J ^a,b,c  

^a UNIVERSITY OF ARIZONA   (United States)

^b University of Arizona   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

AKT; Allosteric; Inhibitor; Kinase; Pleckstrin homology domain; Rational drug design

Indexed keywords

2 METHOXY 3 OCTADECYLOXYPROPYL HYDROGEN PHOSPHATE; 2 O BENZYLINOSITOL 1,3,4,5,6 PENTAKIS PHOSPHATE; 3BETA ACETOXYTIRUCALLIC ACID; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; 4 DODECYL N (1,3,4 THIADIAZOL 2 YL)BENZENESULFONAMIDE; DOCETAXEL; EDELFOSINE; GEMCITABINE; MILTEFOSINE; MK 2206; NSC 348900; PACLITAXEL; PEPTIDOMIMETIC AGENT; PERIFOSINE; PH 427; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLINOSITOL 3 PHOSPHATE; PLECKSTRIN; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PYRIDO[2,3 D]PYRIMIDINE DERIVATIVE; SORAFENIB; SULFONAMIDE; SUNITINIB; TERPENOID DERIVATIVE; TIRUCALLIC ACID; TRICIRIBINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; DRUG SCREENING; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; IONIZING RADIATION; LIVER TOXICITY; NONHUMAN; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; SINGLE DRUG DOSE; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD PROTEINS; DRUG EVALUATION; MICE; MODELS, ANIMAL; PHOSPHOPROTEINS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 79959370480     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711796011292     Document Type: Article

References (149)

1. Hawkins, P. T.; Anderson, K. E.; Davidson, K.; Stephens, L. R. Signalling through Class I PI3Ks in mammalian cells. Biochem. Soc. Trans., 2006, 34, 647-662. (Pubitemid 44796393)
2. Toker, A.; Cantley, L. C. Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature, 1997, 387, 673-676. (Pubitemid 27270600)
3. Carpenter, C. L.; Cantley, L. C. Phosphoinositide kinases. Biochemistry, 1990, 29, 11147-11156.
4. Sjolander, A.; Yamamoto, K.; Huber, B. E.; Lapetina, E. G. Association of p21ras with phosphatidylinositol 3-kinase. Proc. Natl. Acad. Sci. U. S. A., 1991, 88, 7908-7912.
5. Maffucci, T.; Falasca, M. Specificity in pleckstrin homology (PH) domain membrane targeting: a role for a phosphoinositide-protein co-operative mechanism. FEBS Lett., 2001, 506, 173-179. (Pubitemid 32964808)
6. Lemmon, M. A.; Ferguson, K. M.; Abrams, C. S. Pleckstrin homology domains and the cytoskeleton. FEBS Lett., 2002, 513, 71-76. (Pubitemid 34242981)
7. Ingley, E.; Hemmings, B. A. Pleckstrin homology (PH) domains in signal transduction. J. Cell. Biochem., 1994, 56, 436-443.
8. Samuels, Y.; Wang, Z.; Bardelli, A.; Silliman, N.; Ptak, J.; Szabo, S.; Yan, H.; Gazdar, A.; Powell, S. M.; Riggins, G. J.; Willson, J. K.; Markowitz, S.; Kinzler, K. W.; Vogelstein, B.; Velculescu, V. E. High frequency of mutations of the PIK3CA gene in human cancers. Science, 2004, 304, 554. (Pubitemid 38541907)
9. Maehama, T.; Dixon, J. E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3, 4, 5-trisphosphate. J. Biol. Chem., 1998, 273, 13375-13378. (Pubitemid 28268370)
10. Wu, X.; Senechal, K.; Neshat, M. S.; Whang, Y. E.; Sawyers, C. L. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. U. S. A., 1998, 95, 15587-15591. (Pubitemid 29018743)
11. Cantley, L. C.; Neel, B. G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. U. S. A., 1999, 96, 4240-4245. (Pubitemid 29190320)
12. Alessi, D. R.; James, S. R.; Downes, C. P.; Holmes, A. B.; Gaffney, P. R.; Reese, C. B.; Cohen, P. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr. Biol., 1997, 7, 261-269. (Pubitemid 27176852)
13. Ihle, N. T.; Powis, G. Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Mol. Can. Ther., 2009, 8, 1-9.
14. Lindsley, C. W.; Zhao, Z.; Leister, W. H.; Robinson, R. G.; Barnett, S. F.; Defeo-Jones, D.; Jones, R. E.; Hartman, G. D.; Huff, J. R.; Huber, H. E.; Duggan, M. E. Allosteric AKT (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg. Med. Chem. Lett., 2005, 15, 761-764. (Pubitemid 40143162)
15. Li, Q.; Li, T.; Zhu, G. D.; Gong, J.; Claibone, A.; Dalton, C.; Luo, Y.; Johnson, E. F.; Shi, Y.; Liu, X.; Klinghofer, V.; Bauch, J. L.; Marsh, K. C.; Bouska, J. J.; Arries, S.; De Jong, R.; Oltersdorf, T.; Stoll, V. S.; Jakob, C. G.; Rosenberg, S. H.; Giranda, V. L. Discovery of trans-3, 4'- bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/AKT) for the treatment of cancer: Synthesis and biological evaluation. Bioorg. Med. Chem. Lett., 2006, 16, 1679-1685. (Pubitemid 43197545)
16. Kumar, C. C.; Madison, V. AKT crystal structure and AKT-specific inhibitors. Oncogene, 2005, 24, 7493-7501. (Pubitemid 41637989)
17. Luo, Y.; Shoemaker, A. R.; Liu, X.; Woods, K. W.; Thomas, S. A.; de Jong, R.; Han, E. K.; Li, T.; Stoll, V. S.; Powlas, J. A.; Oleksijew, A.; Mitten, M. J.; Shi, Y.; Guan, R.; McGonigal, T. P.; Klinghofer, V.; Johnson, E. F.; Leverson, J. D.; Bouska, J. J.; Mamo, M.; Smith, R. A.; Gramling-Evans, E. E.; Zinker, B. A.; Mika, A. K.; Nguyen, P. T.; Oltersdorf, T.; Rosenberg, S. H.; Li, Q.; Giranda, V. L. Potent and selective inhibitors of AKT kinases slow the progress of tumors in vivo. Mol. Can. Ther., 2005, 4, 977-986. (Pubitemid 40909080)
18. Hoffman, K.; Holmes, F. A.; Fraschini, G.; Esparza, L.; Frye, D.; Raber, M. N.; Newman, R. A.; Hortobagyi, G. N. Phase I-II study: triciribine (tricyclic nucleoside phosphate) for metastatic breast cancer. Can. Chem. Pharmacol., 1996, 37, 254-258.
19. Zhu, G. D.; Gandhi, V. B.; Gong, J.; Thomas, S.; Woods, K. W.; Song, X.; Li, T.; Diebold, R. B.; Luo, Y.; Liu, X.; Guan, R.; Klinghofer, V.; Johnson, E. F.; Bouska, J.; Olson, A.; Marsh, K. C.; Stoll, V. S.; Mamo, M.; Polakowski, J.; Campbell, T. J.; Martin, R. L.; Gintant, G. A.; Penning, T. D.; Li, Q.; Rosenberg, S. H.; Giranda, V. L. Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/AKT inhibitors with reduced hypotension. J. Med. Chem., 2007, 50, 2990-3003. (Pubitemid 47001242)
20. Cho, H.; Mu, J.; Kim, J. K.; Thorvaldsen, J. L.; Chu, Q.; Crenshaw, E. B., 3rd; Kaestner, K. H.; Bartolomei, M. S.; Shulman, G. I.; Birnbaum, M. J. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase AKT2 (PKB beta). Science, 2001, 292, 1728-1731. (Pubitemid 32506248)
21. Cheng, A. Y.; Fantus, I. G. Oral antihyperglycemic therapy for type 2 diabetes mellitus. Can. Med. Ass. J., 2005, 172, 213-226.
22. Crouthamel, M. C.; Kahana, J. A.; Korenchuk, S.; Zhang, S. Y.; Sundaresan, G.; Eberwein, D. J.; Brown, K. K.; Kumar, R. Mechanism and management of AKT inhibitor-induced hyperglycemia. Clin. Can. Res., 2009, 15, 217-225.
23. Marte, B. M.; Downward, J. PKB/AKT: connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem. Sci., 1997, 22, 355-358.
24. Coffer, P. J.; Jin, J.; Woodgett, J. R. Protein kinase B (c-AKT): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem. J., 1998, 335, 1-13. (Pubitemid 28477043)
25. Masure, S.; Haefner, B.; Wesselink, J. J.; Hoefnagel, E.; Mortier, E.; Verhasselt, P.; Tuytelaars, A.; Gordon, R.; Richardson, A. Molecular cloning, expression and characterization of the human serine/threonine kinase AK T-3. Eu r. J. Biochem., 1999, 265, 353-360. (Pubitemid 29466045)
26. Nakatani, K.; Thompson, D. A.; Barthel, A.; Sakaue, H.; Liu, W.; Weigel, R. J.; Roth, R. A. Up-regulation of AKT3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J. Biol. Chem., 1999, 274, 21528-21532.
27. Scheid, M. P.; Woodgett, J. R. Unravelling the activation mechanisms of protein kinase B/AKT. FEBS Lett., 2003, 546, 108-112. (Pubitemid 36782290)
28. Rebecchi, M. J.; Scarlata, S. Pleckstrin homology domains: a common fold with diverse functions. Ann. Rev. Biophys. Biomol. Struct., 1998, 27, 503-528. (Pubitemid 28286023)
29. Laine, J.; Kunstle, G.; Obata, T.; Sha, M.; Noguchi, M. The protooncogene TCL1 is an AKT kinase coactivator. Mol. Cell., 2000, 6, 395-407.
30. Auguin, D.; Barthe, P.; Auge-Senegas, M. T.; Stern, M. H.; Noguchi, M.; Roumestand, C. Solution structure and backbone dynamics of the pleckstrin homology domain of the human protein kinase B (PKB/AKT). Interaction with inositol phosphates. J. Biomol. NMR., 2004, 28, 137-155. (Pubitemid 38232793)
31. Auguin, D.; Barthe, P.; Royer, C.; Stern, M. H.; Noguchi, M.; Arold, S. T.; Roumestand, C. Structural basis for the co-activation of protein kinase B by T-cell leukemia-1 (TCL1) family proto-oncoproteins. J. Biol. Chem., 2004, 279, 35890-35902. (Pubitemid 39100596)
32. Cantley, L. C. The phosphoinositide 3-kinase pathway. Science, 2002, 296, 1655-1657. (Pubitemid 34579158)
33. Skeen, J. E.; Bhaskar, P. T.; Chen, C. C.; Chen, W. S.; Peng, X. D.; Nogueira, V.; Hahn-Windgassen, A.; Kiyokawa, H.; Hay, N. AKT deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. Can. Cell., 2006, 10, 269-280. (Pubitemid 44512190)
34. Schwertfeger, K. L.; Richert, M. M.; Anderson, S. M. Mammary gland involution is delayed by activated AKT in transgenic mice. Mol. Endocrinol., 2001, 15, 867-881. (Pubitemid 32510636)
35. Malstrom, S.; Tili, E.; Kappes, D.; Ceci, J. D.; Tsichlis, P. N. Tumor induction by an Lck-MyrAKT transgene is delayed by mechanisms controlling the size of the thymus. Proc. Natl. Acad. Sci. U. S. A., 2001, 98, 14967-14972. (Pubitemid 34013953)
36. Ackler, S.; Ahmad, S.; Tobias, C.; Johnson, M. D.; Glazer, R. I. Delayed mammary gland involution in MMTV-AKT1 transgenic mice. Oncogene, 2002, 21, 198-206. (Pubitemid 34102128)
37. Chen, M. L.; Xu, P. Z.; Peng, X. D.; Chen, W. S.; Guzman, G.; Yang, X.; Di Cristofano, A.; Pandolfi, P. P.; Hay, N. The deficiency of AKT1 is sufficient to suppress tumor development in Pten+/-mice. Genes Dev., 2006, 20, 1569-1574. (Pubitemid 43901096)
38. Cheng, J. Q.; Ruggeri, B.; Klein, W. M.; Sonoda, G.; Altomare, D. A.; Watson, D. K.; Testa, J. R. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc. Natl. Acad. Sci. U. S. A., 1996, 93, 3636-3641. (Pubitemid 26127592)
39. Nicholson, K. M.; Anderson, N. G. The protein kinase B/AKT signalling pathway in human malignancy. Cell Signal., 2002, 14, 381-395. (Pubitemid 34214843)
40. Datta, S. R.; Dudek, H.; Tao, X.; Masters, S.; Fu, H.; Gotoh, Y.; Greenberg, M. E. AKT phosphorylation of BAD couples survival signals to the cellintrinsic death machinery. Cell, 1997, 91, 231-241. (Pubitemid 27456390)
41. Kim, A. H.; Khursigara, G.; Sun, X.; Franke, T. F.; Chao, M. V. AKT phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol. Cell. Biol., 2001, 21, 893-901. (Pubitemid 32104737)
42. Cardone, M. H.; Roy, N.; Stennicke, H. R.; Salvesen, G. S.; Franke, T. F.; Stanbridge, E.; Frisch, S.; Reed, J. C. Regulation of cell death protease caspase-9 by phosphorylation. Science, 1998, 282, 1318-1321. (Pubitemid 28524494)
43. Ozes, O. N.; Mayo, L. D.; Gustin, J. A.; Pfeffer, S. R.; Pfeffer, L. M.; Donner, D. B. NF-kappaB activation by tumour necrosis factor requires the AKT serine-threonine kinase. Nature. 1999, 401, 82-85.
44. Du, K.; Montminy, M. CREB is a regulatory target for the protein kinase AKT/PKB. J. Biol. Chem., 1998, 273, 32377-32379. (Pubitemid 28557606)
45. Chung, J.; Grammer, T. C.; Lemon, K. P.; Kazlauskas, A.; Blenis, J. PDGF-and insulin-dependent pp70S6k activation mediated by phosphatidylinositol- 3-OH kinase. Nature, 1994, 370, 71-75.
46. van Weeren, P. C.; de Bruyn, K. M.; de Vries-Smits, A. M.; van Lint, J.; Burgering, B. M. Essential role for protein kinase B (PKB) in insulin-induced glycogen synthase kinase 3 inactivation. Characterization of dominantnegative mutant of PKB. J. Biol. Chem., 1998, 273, 13150-13156. (Pubitemid 28246883)
47. Kerbel, R. S.; Yu, J.; Tran, J.; Man, S.; Viloria-Petit, A.; Klement, G.; Coomber, B. L.; Rak, J. Possible mechanisms of acquired resistance to antiangiogenic drugs: implications for the use of combination therapy approaches. Can. Met. Rev., 2001, 20, 79-86. (Pubitemid 34074682)
48. Lemmon, M. A. Pleckstrin homology (PH) domains and phosphoinositides. Biochem. Soc. Symp., 2007, 81-93.
49. Carman, C. V.; Barak, L. S.; Chen, C.; Liu-Chen, L. Y.; Onorato, J. J.; Kennedy, S. P.; Caron, M. G.; Benovic, J. L. Mutational analysis of Gbetagamma and phospholipid interaction with G protein-coupled receptor kinase 2. J. Biol. Chem., 2000, 275, 10443-10452. (Pubitemid 30202105)
50. Lodowski, D. T.; Pitcher, J. A.; Capel, W. D.; Lefkowitz, R. J.; Tesmer, J. J. Keeping G proteins at bay: a complex between G protein-coupled receptor kinase 2 and Gbetagamma. Science, 2003, 300, 1256-1262. (Pubitemid 36618232)
51. Mahadevan, D.; Thanki, N.; Singh, J.; McPhie, P.; Zangrilli, D.; Wang, L. M.; Guerrero, C.; LeVine, H., 3rd; Humblet, C.; Saldanha, J.; et al. Structural studies on the PH domains of Db1, Sos1, IRS-1, and beta ARK1 and their differential binding to G beta gamma subunits. Biochemistry, 1995, 34, 9111-9117.
52. Touhara, K.; Inglese, J.; Pitcher, J. A.; Shaw, G.; Lefkowitz, R. J. Binding of G protein beta gamma-subunits to pleckstrin homology domains. J. Biol. Chem., 1994, 269, 10217-10220. (Pubitemid 24198209)
53. Park, W. S.; Heo, W. D.; Whalen, J. H.; O'Rourke, N. A.; Bryan, H. M.; Meyer, T.; Teruel, M. N. Comprehensive identification of PIP3-regulated PH domains from C. elegans to H. sapiens by model prediction and live imaging. Mol. Cell., 2008, 30, 381-392. (Pubitemid 351615320)
54. Hurley, J. H.; Misra, S. Signaling and subcellular targeting by membranebinding domains. Ann. Rev. Biophys. Biomol. Struct., 2000, 29, 49-79. (Pubitemid 30599588)
55. Bellacosa, A.; Chan, T. O.; Ahmed, N. N.; Datta, K.; Malstrom, S.; Stokoe, D.; McCormick, F.; Feng, J.; Tsichlis, P. AKT activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene, 1998, 17, 313-325. (Pubitemid 28383008)
56. Rong, S. B.; Hu, Y.; Enyedy, I.; Powis, G.; Meuillet, E. J.; Wu, X.; Wang, R.; Wang, S.; Kozikowski, A. P. Molecular modeling studies of the AKT PH domain and its interaction with phosphoinositides. J. Med. Chem., 2001, 44, 898-908. (Pubitemid 32861614)
57. Thomas, C. C.; Deak, M.; Alessi, D. R.; van Aalten, D. M. High-resolution structure of the pleckstrin homology domain of protein kinase b/AKT bound to phosphatidylinositol (3, 4, 5)-trisphosphate. Curr. Biol., 2002, 12, 1256-1262. (Pubitemid 34801176)
58. Milburn, C. C.; Deak, M.; Kelly, S. M.; Price, N. C.; Alessi, D. R.; Van Aalten, D. M. Binding of phosphatidylinositol 3, 4, 5-trisphosphate to the pleckstrin homology domain of protein kinase B induces a conformational change. Biochem. J., 2003, 375, 531-538. (Pubitemid 37433501)
59. Frech, M.; Andjelkovic, M.; Ingley, E.; Reddy, K. K.; Falck, J. R.; Hemmings, B. A. High affinity binding of inositol phosphates and phosphoinositides to the pleckstrin homology domain of RAC/protein kinase B and their influence on kinase activity. J. Biol. Chem., 1997, 272, 8474-8481. (Pubitemid 27147810)
60. James, S. R.; Downes, C. P.; Gigg, R.; Grove, S. J.; Holmes, A. B.; Alessi, D. R. Specific binding of the AKT-1 protein kinase to phosphatidylinositol 3, 4, 5-trisphosphate without subsequent activation. Biochem. J., 1996, 315(Pt 3), 709-713. (Pubitemid 26147592)
61. Gambhir, A.; Hangyas-Mihalyne, G.; Zaitseva, I.; Cafiso, D. S.; Wang, J.; Murray, D.; Pentyala, S. N.; Smith, S. O.; McLaughlin, S. Electrostatic sequestration of PIP2 on phospholipid membranes by basic/aromatic regions of proteins. Biophys. J., 2004, 86, 2188-2207. (Pubitemid 38524409)
62. Calleja, V.; Laguerre, M.; Parker, P. J.; Larijani, B. Role of a novel PH-kinase domain interface in PKB/AKT regulation: structural mechanism for allosteric inhibition. PLoS Biol., 2009, 7, e17.
63. Calleja, V.; Laguerre, M.; Larijani, B. 3-D structure and dynamics of protein kinase B-new mechanism for the allosteric regulation of an AGC kinase. J. Chem. Biol., 2009, 2, 11-25.
64. Yang, J.; Cron, P.; Good, V. M.; Thompson, V.; Hemmings, B. A.; Barford, D. Crystal structure of an activated AKT/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nat. Struct. Biol., 2002, 9, 940-944. (Pubitemid 35417064)
65. Alessi, D. R.; Cohen, P. Mechanism of activation and function of protein kinase B. Curr. Opin. Genet. Dev., 1998, 8, 55-62. (Pubitemid 28122141)
66. Hresko, R. C.; Mueckler, M. mTOR. RICTOR is the Ser473 kinase for AKT/protein kinase B in 3T3-L1 adipocytes. J. Biol. Chem., 2005, 280, 40406-40416. (Pubitemid 41780527)
67. Feng, J.; Park, J.; Cron, P.; Hess, D.; Hemmings, B. A. Identification of a PKB/AKT hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J. Biol. Chem., 2004, 279, 41189-41196. (Pubitemid 39287721)
68. Toker, A.; Newton, A. C. AKT/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site. J. Biol. Chem., 2000, 275, 8271-8274. (Pubitemid 30180163)
69. Datta, K.; Franke, T. F.; Chan, T. O.; Makris, A.; Yang, S. I.; Kaplan, D. R.; Morrison, D. K.; Golemis, E. A.; Tsichlis, P. N. AH/PH domain-mediated interaction between AKT molecules and its potential role in AKT regulation. Mol. Cell. Biol., 1995, 15, 2304-2310.
70. Chan, T. O.; Rittenhouse, S. E.; Tsichlis, P. N. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositidedependent phosphorylation. Ann. Rev. Biochem., 1999, 68, 965-1014. (Pubitemid 29449213)
71. Jacobs, M.; Hayakawa, K.; Swenson, L.; Bellon, S.; Fleming, M.; Taslimi, P.; Doran, J. The structure of dimeric ROCK I reveals the mechanism for ligand selectivity. J. Biol. Chem., 2006, 281, 260-268. (Pubitemid 43671185)
72. Fushman, D.; Cahill, S.; Cowburn, D. The main-chain dynamics of the dynamin pleckstrin homology (PH) domain in solution: analysis of 15N relaxation with monomer/dimer equilibration. J. Mol. Biol., 1997, 266, 173-194. (Pubitemid 27170527)
73. Powis, G.; Aksoy, I. A.; Melder, D. C.; Aksoy, S.; Eichinger, H.; Fauq, A. H.; Kozikowski, A. P. D-3-deoxy-3-substituted myo-inositol analogues as inhibitors of cell growth. Can. Chemother. Pharmacol., 1991, 29, 95-104.
74. Hu, Y.; Meuillet, E. J.; Berggren, M.; Powis, G.; Kozikowski, A. P. 3-Deoxy-3-substituted-D-myo-inositol imidazolyl ether lipid phosphates and carbonate as inhibitors of the phosphatidylinositol 3-kinase pathway and cancer cell growth. Bioorg. Med. Chem. Lett., 2001, 11, 173-176. (Pubitemid 32099634)
75. Hu, Y.; Qiao, L.; Wang, S.; Rong, S. B.; Meuillet, E. J.; Berggren, M.; Gallegos, A.; Powis, G.; Kozikowski, A. P. 3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, AKT, and cancer cell growth. J. Med. Chem., 2000, 43, 3045-3051. (Pubitemid 30626762)
76. Qiao, L.; Nan, F.; Kunkel, M.; Gallegos, A.; Powis, G.; Kozikowski, A. P. 3-Deoxy-D-myo-inositol 1-phosphate, 1-phosphonate, and ether lipid analogues as inhibitors of phosphatidylinositol-3-kinase signaling and cancer cell growth. J. Med. Chem., 1998, 41, 3303-3306. (Pubitemid 28406536)
77. Li, Q. Recent progress in computer-aided diagnosis of lung nodules on thinsection CT. Comput. Med. Imaging Graph., 2007, 31, 248-257. (Pubitemid 46604787)
78. Meuillet, E. J.; Mahadevan, D.; Vankayalapati, H.; Berggren, M.; Williams, R.; Coon, A.; Kozikowski, A. P.; Powis, G. Specific inhibition of the AKT1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myo-inositol analogues. Mol. Can. Ther., 2003, 2, 389-399.
79. Berkovic, D. Cytotoxic etherphospholipid analogues. Gen. Pharmacol., 1998, 31, 511-517. (Pubitemid 28458917)
80. Meuillet, E. J.; Ihle, N.; Baker, A. F.; Gard, J. M.; Stamper, C.; Williams, R.; Coon, A.; Mahadevan, D.; George, B. L.; Kirkpatrick, L.; Powis, G. In vivo molecular pharmacology and antitumor activity of the targeted AKT inhibitor PX-316. Oncol. Res., 2004, 14, 513-527. (Pubitemid 39551564)
81. Egorin, M., Plasma pharmacokinetics and bioavailability for the phosphatidylinositide-3-kinase signaling inhibitor, OMDPI (NSC 710297) in CDF2F1 mice. Proc. Am. Assoc. Cancer Res., 2002, 604.
82. Martelli, A. M.; Tazzari, P. L.; Tabellini, G.; Bortul, R.; Billi, A. M.; Manzoli, L.; Ruggeri, A.; Conte, R.; Cocco, L. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-transretinoic acid, and ionizing radiation of human leukemia cells. Leukemia, 2003, 17, 1794-1805. (Pubitemid 37185255)
83. Modolell, M.; Andreesen, R.; Pahlke, W.; Brugger, U.; Munder, P. G. Disturbance of phospholipid metabolism during the selective destruction of tumor cells induced by alkyl-lysophospholipids. Cancer Res., 1979, 39, 4681-4686. (Pubitemid 10198650)
84. Andreesen, R.; Modolell, M.; Munder, P. G. Selective sensitivity of chronic myelogenous leukemia cell populations to alkyl-lysophospholipids. Blood, 1979, 54, 519-523. (Pubitemid 9247720)
85. Andreesen, R.; Modolell, M.; Weltzien, H. U.; Eibl, H.; Common, H. H.; Lohr, G. W.; Munder, P. G. Selective destruction of human leukemic cells by alkyl-lysophospholipids. Cancer Res., 1978, 38, 3894-3899. (Pubitemid 9046345)
86. van Blitterswijk, W. J.; Verheij, M. Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects. Curr. Pharm. Des., 2008, 14, 2061-2074.
87. Berkovic, D.; Grundel, O.; Berkovic, K.; Wildfang, I.; Hess, C. F.; Schmoll, H. J. Synergistic cytotoxic effects of ether phospholipid analogues and ionizing radiation in human carcinoma cells. Radiother. Oncol., 1997, 43, 293-301. (Pubitemid 27248476)
88. Vink, S. R.; van Blitterswijk, W. J.; Schellens, J. H.; Verheij, M. Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy. Cancer Treat. Rev., 2007, 33, 191-202. (Pubitemid 46323398)
89. Gills, J. J.; Dennis, P. A. Perifosine: update on a novel AKT inhibitor. Curr. Oncol. Rep., 2009, 11, 102-110.
90. Richardson, P. G.; Sonneveld, P.; Schuster, M. W.; Irwin, D.; Stadtmauer, E. A.; Facon, T.; Harousseau, J. L.; Ben-Yehuda, D.; Lonial, S.; San Miguel, J. F.; Cavenagh, J. D.; Anderson, K. C. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br. J. Haematol., 2007, 137, 429-435. (Pubitemid 46698286)
91. Hilgard, P.; Klenner, T.; Stekar, J.; Nossner, G.; Kutscher, B.; Engel, J. D-21266, a new heterocyclic alkylphospholipid with antitumour activity. Eur. J. Cancer., 1997, 33, 442-446. (Pubitemid 27168072)
92. Stekar, J.; Hilgard, P.; Voegeli, R.; Maurer, H. R.; Engel, J.; Kutscher, B.; Nossner, G.; Schumacher, W. Antineoplastic activity and tolerability of a novel heterocyclic alkylphospholipid, D-20133. Cancer Chemother. Pharmacol., 1993, 32, 437-444. (Pubitemid 23234660)
93. Ruiter, G. A.; Verheij, M.; Zerp, S. F.; van Blitterswijk, W. J. Alkyllysophospholipids as anticancer agents and enhancers of radiation-induced apoptosis. Int. J. Radiat. Oncol. Biol. Phys., 2001, 49, 415-419. (Pubitemid 32120238)
94. Ruiter, G. A.; Zerp, S. F.; Bartelink, H.; van Blitterswijk, W. J.; Verheij, M. Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-AKT/PKB survival pathway. Anticancer Drugs, 2003, 14, 167-173. (Pubitemid 36269756)
95. Kondapaka, S. B.; Singh, S. S.; Dasmahapatra, G. P.; Sausville, E. A.; Roy, K. K. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol. Can. Ther., 2003, 2, 1093-1103.
96. Meuillet, E. J.; Zuohe, S.; Lemos, R.; Ihle, N.; Kingston, J.; Watkins, R.; Moses, S. A.; Zhang, S.; Du-Cuny, L.; Herbst, R.; Jacoby, J. J.; Zhou, L. L.; Ahad, A. M.; Mash, E. A.; Kirkpatrick, D. L.; Powis, G. Molecular pharmacology and antitumor activity of PHT-427, a novel AKT/ phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol. Can. Ther., 2010, 9, 706-717.
97. Poradosu, E. Perifosine selectively inhibits binding of AKT PH domain to PtdIns (3, 4) P2. Proc. Am. Assoc. Cancer Res., 2007, 1645.
98. Hideshima, T.; Catley, L.; Yasui, H.; Ishitsuka, K.; Raje, N.; Mitsiades, C.; Podar, K.; Munshi, N. C.; Chauhan, D.; Richardson, P. G.; Anderson, K. C. Perifosine, an oral bioactive novel alkylphospholipid, inhibits AKT and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood, 2006, 107, 4053-4062. (Pubitemid 43726814)
99. LoPiccolo, J.; Blumenthal, G. M.; Bernstein, W. B.; Dennis, P. A. Targeting the PI3K/AKT/mTOR pathway: effective combinations and clinical considerations. Drug Resist, Updat., 2008, 11, 32-50.
100. Hennessy, B. T.; Lu, Y.; Poradosu, E.; Yu, Q.; Yu, S.; Hall, H.; Carey, M. S.; Ravoori, M.; Gonzalez-Angulo, A. M.; Birch, R.; Henderson, I. C.; Kundra, V.; Mills, G. B. Pharmacodynamic markers of perifosine efficacy. Clin. Cancer Res., 2007, 13, 7421-7431.
101. Vink, S. R.; Schellens, J. H.; van Blitterswijk, W. J.; Verheij, M. Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid. Invest. New Drugs, 2005, 23, 279-286. (Pubitemid 40980350)
102. Breiser, A.; Kim, D. J.; Fleer, E. A.; Damenz, W.; Drube, A.; Berger, M.; Nagel, G. A.; Eibl, H.; Unger, C. Distribution and metabolism of hexadecylphosphocholine in mice. Lipids, 1987, 22, 925-926. (Pubitemid 18001398)
103. Crul, M.; Rosing, H.; de Klerk, G. J.; Dubbelman, R.; Traiser, M.; Reichert, S.; Knebel, N. G.; Schellens, J. H.; Beijnen, J. H.; Ten Bokkel Huinink, W. W. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur. J. Cancer, 2002, 38, 1615-1621. (Pubitemid 34876501)
104. Van Ummersen, L.; Binger, K.; Volkman, J.; Marnocha, R.; Tutsch, K.; Kolesar, J.; Arzoomanian, R.; Alberti, D.; Wilding, G. A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin. Cancer Res., 2004, 10, 7450-7456. (Pubitemid 39557506)
105. Castillo, S. S.; Brognard, J.; Petukhov, P. A.; Zhang, C.; Tsurutani, J.; Granville, C. A.; Li, M.; Jung, M.; West, K. A.; Gills, J. G.; Kozikowski, A. P.; Dennis, P. A. Preferential inhibition of AKT and killing of AKT-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues. Cancer Res., 2004, 64, 2782-2792. (Pubitemid 38500616)
106. Kozikowski, A. P.; Sun, H.; Brognard, J.; Dennis, P. A. Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase AKT. J. Am. Chem. Soc., 2003, 125, 1144-1145. (Pubitemid 36159806)
107. Gills, J. J.; Holbeck, S.; Hollingshead, M.; Hewitt, S. M.; Kozikowski, A. P.; Dennis, P. A. Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of AKT. Mol. Can. Ther., 2006, 5, 713-722.
108. Memmott, R. M.; Gills, J. J.; Hollingshead, M.; Powers, M. C.; Chen, Z.; Kemp, B.; Kozikowski, A.; Dennis, P. A. Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells. Cancer Res., 2008, 68, 580-588. (Pubitemid 351380087)
109. Gills, J. J.; Castillo, S. S.; Zhang, C.; Petukhov, P. A.; Memmott, R. M.; Hollingshead, M.; Warfel, N.; Han, J.; Kozikowski, A. P.; Dennis, P. A. Phosphatidylinositol ether lipid analogues that inhibit AKT also independently activate the stress kinase, p38alpha, through MKK3/6-independent and-dependent mechanisms. J. Biol. Chem., 2007, 282, 27020-27029. (Pubitemid 47501968)
110. Berrie, C. P.; Falasca, M. Patterns within protein/polyphosphoinositide interactions provide specific targets for therapeutic intervention. FASEB J., 2000, 14, 2618-2622.
111. Razzini, G.; Berrie, C. P.; Vignati, S.; Broggini, M.; Mascetta, G.; Brancaccio, A.; Falasca, M. Novel functional PI 3-kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell lines. FASEB J., 2000, 14, 1179-1187. (Pubitemid 30350400)
112. Piccolo, E.; Vignati, S.; Maffucci, T.; Innominato, P. F.; Riley, A. M.; Potter, B. V.; Pandolfi, P. P.; Broggini, M.; Iacobelli, S.; Innocenti, P.; Falasca, M. Inositol pentakisphosphate promotes apoptosis through the PI 3-K/AKT pathway. Oncogene, 2004, 23, 1754-1765. (Pubitemid 38445167)
113. Maffucci, T.; Piccolo, E.; Cumashi, A.; Iezzi, M.; Riley, A. M.; Saiardi, A.; Godage, H. Y.; Rossi, C.; Broggini, M.; Iacobelli, S.; Potter, B. V.; Innocenti, P.; Falasca, M. Inhibition of the phosphatidylinositol 3-kinase/AKT pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects. Cancer Res., 2005, 65, 8339-8349. (Pubitemid 41330599)
114. Jenab, M.; Thompson, L. U. Phytic acid in wheat bran affects colon morphology, cell differentiation and apoptosis. Carcinogenesis, 2000, 21, 1547-1552. (Pubitemid 30603979)
115. Raina, K.; Rajamanickam, S.; Singh, R. P.; Agarwal, R. Chemopreventive efficacy of inositol hexaphosphate against prostate tumor growth and progression in TRAMP mice. Clin. Cancer Res., 2008, 14, 3177-3184.
116. Lee, H. J.; Lee, S. A.; Choi, H. Dietary administration of inositol and/or inositol-6-phosphate prevents chemically-induced rat hepatocarcinogenesis. Asian Pac. J. Cancer Prev., 2005, 6, 41-47.
117. Falasca, M.; Chiozzotto, D.; Godage, H. Y.; Mazzoletti, M.; Riley, A. M.; Previdi, S.; Potter, B. V.; Broggini, M.; Maffucci, T. A novel inhibitor of the PI3K/AKT pathway based on the structure of inositol 1, 3, 4, 5, 6-pentakisphosphate. Br. J. Cancer, 2010, 102, 104-114.
118. Mills, S. J.; Komander, D.; Trusselle, M. N.; Safrany, S. T.; van Aalten, D. M.; Potter, B. V. Novel inositol phospholipid headgroup surrogate crystallized in the pleckstrin homology domain of protein kinase Balpha. ACS Chem. Biol., 2007, 2, 242-246. (Pubitemid 47629211)
119. Masters, T. A.; Calleja, V.; Armoogum, D. A.; Marsh, R. J.; Applebee, C. J.; Laguerre, M.; Bain, A. J.; Larijani, B. Regulation of 3- phosphoinositidedependent protein kinase 1 activity by homodimerization in live cells. Sci. Signal., 2010, 3, ra78.
120. Chakraborty, A.; Koldobskiy, M. A.; Bello, N. T.; Maxwell, M.; Potter, J. J.; Juluri, K. R.; Maag, D.; Kim, S.; Huang, A. S.; Dailey, M. J.; Saleh, M.; Snowman, A. M.; Moran, T. H.; Mezey, E.; Snyder, S. H. Inositol pyrophosphates inhibit AKT signaling, thereby regulating insulin sensitivity and weight gain. Cell, 2010, 143, 897-910.
121. Mahadevan, D.; Powis, G.; Mash, E. A.; George, B.; Gokhale, V. M.; Zhang, S.; Shakalya, K.; Du-Cuny, L.; Berggren, M.; Ali, M. A.; Jana, U.; Ihle, N.; Moses, S.; Franklin, C.; Narayan, S.; Shirahatti, N.; Meuillet, E. J. Discovery of a novel class of AKT pleckstrin homology domain inhibitors. Mol. Can. Ther., 2008, 7, 2621-2632.
122. Moses, S. A.; Ali, M. A.; Zuohe, S.; Du-Cuny, L.; Zhou, L. L.; Lemos, R.; Ihle, N.; Skillman, A. G.; Zhang, S.; Mash, E. A.; Powis, G.; Meuillet, E. J. In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT. Cancer Res., 2009, 69, 5073-5081.
123. Du-Cuny, L.; Song, Z.; Moses, S.; Powis, G.; Mash, E. A.; Meuillet, E. J.; Zhang, S. Computational modeling of novel inhibitors targeting the AKT pleckstrin homology domain. Bioorg. Med. Chem., 2009, 17, 6983-6992.
124. Ihle, N. T.; Lemos, R., Jr.; Wipf, P.; Yacoub, A.; Mitchell, C.; Siwak, D.; Mills, G. B.; Dent, P.; Kirkpatrick, D. L.; Powis, G. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res., 2009, 69, 143-150.
125. Casanova, A.; Moses, S.; Morgan, S.; Mash, E.; Powis, G.; Meuillet, E. A novel inhibitor of AKT prevents UVB-induced signaling in human skin cancers. Proc. Am. Assoc. Cancer Res., 2009, 3709.
126. Wotring, L. L.; Townsend, L. B.; Jones, L. M.; Borysko, K. Z.; Gildersleeve, D. L.; Parker, W. B. Dual mechanisms of inhibition of DNA synthesis by triciribine. Cancer Res., 1990, 50, 4891-4899. (Pubitemid 20257905)
127. Schweinsberg, P. D.; Smith, R. G.; Loo, T. L. Identification of the metabolites of an antitumor tricyclic nucleoside (NSC-154020). Biochem. Pharmacol., 1981, 30, 2521-2526. (Pubitemid 11042498)
128. Ptak, R. G.; Borysko, K. Z.; Porcari, A. R.; Buthod, J. L.; Holland, L. E.; Shipman, C., Jr.; Townsend, L. B.; Drach, J. C. Phosphorylation of triciribine is necessary for activity against HIV type 1. AIDS Res. Hum. Retroviruses, 1998, 14, 1315-1322. (Pubitemid 28465265)
129. Yang, L.; Dan, H. C.; Sun, M.; Liu, Q.; Sun, X. M.; Feldman, R. I.; Hamilton, A. D.; Polokoff, M.; Nicosia, S. V.; Herlyn, M.; Sebti, S. M.; Cheng, J. Q. AKT/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of AKT signaling with antitumor activity in cancer cells overexpressing AKT. Cancer Res., 2004, 64, 4394-4399. (Pubitemid 38856907)
130. Lu, C. H.; Wyszomierski, S. L.; Tseng, L. M.; Sun, M. H.; Lan, K. H.; Neal, C. L.; Mills, G. B.; Hortobagyi, G. N.; Esteva, F. J.; Yu, D. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin. Cancer Res., 2007, 13, 5883-5888. (Pubitemid 47583915)
131. Berndt, N.; Yang, H.; Trinczek, B.; Betzi, S.; Zhang, Z.; Wu, B.; Lawrence, N. J.; Pellecchia, M.; Schonbrunn, E.; Cheng, J. Q.; Sebti, S. M. The AKT activation inhibitor TCN-P inhibits AKT phosphorylation by binding to the PH domain of AKT and blocking its recruitment to the plasma membrane. Cell Death Differ., 2010, 17, 1795-1804.
132. Wotring, L. L.; Crabtree, G. W.; Edwards, N. L.; Parks, R. E., Jr.; Townsend, L. B. Mechanism of activation of triciribine phosphate (TCN-P) as a prodrug form of TCN. Cancer Treat. Rep., 1986, 70, 491-497. (Pubitemid 16116454)
133. Garrett, C. R.; Coppola, D.; Wenham, R. M.; Cubitt, C. L.; Neuger, A. M.; Frost, T. J.; Lush, R. M.; Sullivan, D. M.; Cheng, J. Q.; Sebti, S. M. Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT. Invest. New Drugs, 2010 (in press).
134. Feun, L. G.; Blessing, J. A.; Barrett, R. J.; Hanjani, P. A phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Study. Am. J. Clin. Oncol., 1993, 16, 506-508.
135. Feun, L. G.; Savaraj, N.; Bodey, G. P.; Lu, K.; Yap, B. S.; Ajani, J. A.; Burgess, M. A.; Benjamin, R. S.; McKelvey, E.; Krakoff, I. Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule. Cancer Res., 1984, 44, 3608-3612. (Pubitemid 14098619)
136. Kim, D.; Sun, M.; He, L.; Zhou, Q. H.; Chen, J.; Sun, X. M.; Bepler, G.; Sebti, S. M.; Cheng, J. Q. A small molecule inhibits AKT through direct binding to AKT and preventing AKT membrane translocation. J. Biol. Chem., 285, 8383-8394.
137. Barnett, S. F.; Bilodeau, M. T.; Lindsley, C. W. The AKT/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation. Curr. Top. Med. Chem., 2005, 5, 109-125. (Pubitemid 40514509)
138. Li, H. F.; Kim, J. S.; Waldman, T. Radiation-induced AKT activation modulates radioresistance in human glioblastoma cells. Radiat. Oncol., 2009, 4, 43.
139. Tolcher, A. A Phase I study of MK-2206, an oral potent allosteric AKT inhibitor (AKTi), in patients (pts) with advanced solid tumor (ST). J. Clin. Oncol., 2009, 27, 15s.
140. Estrada, A. C.; Syrovets, T.; Pitterle, K.; Lunov, O.; Buchele, B.; Schimana-Pfeifer, J.; Schmidt, T.; Morad, S. A.; Simmet, T. Tirucallic acids are novel pleckstrin homology domain-dependent AKT inhibitors inducing apoptosis in prostate cancer cells. Mol. Pharmacol., 77, 378-387.
141. Miao, B.; Skidan, I.; Yang, J.; Lugovskoy, A.; Reibarkh, M.; Long, K.; Brazell, T.; Durugkar, K. A.; Maki, J.; Ramana, C. V.; Schaffhausen, B.; Wagner, G.; Torchilin, V.; Yuan, J.; Degterev, A. Small molecule inhibition of phosphatidylinositol-3, 4, 5-triphosphate (PIP3) binding to pleckstrin homology domains. Proc. Natl. Acad. Sci. U. S. A., 2010, 107, 20126-20131.
142. Hiromura, M.; Okada, F.; Obata, T.; Auguin, D.; Shibata, T.; Roumestand, C.; Noguchi, M. Inhibition of AKT kinase activity by a peptide spanning the betaA strand of the proto-oncogene TCL1. J. Biol. Chem., 2004, 279, 53407-53418. (Pubitemid 40051845)
143. Noguchi, M.; Ropars, V.; Roumestand, C.; Suizu, F. Proto-oncogene TCL1: more than just a coactivator for AKT. FASEB J., 2007, 21, 2273-2284. (Pubitemid 47230657)
144. Powell, D. J.; Hajduch, E.; Kular, G.; Hundal, H. S. Ceramide disables 3-phosphoinositide binding to the pleckstrin homology domain of protein kinase B (PKB)/AKT by a PKCzeta-dependent mechanism. Mol. Cell Biol., 2003, 23, 7794-7808. (Pubitemid 37271476)
145. Ashida, N.; Arai, H.; Yamasaki, M.; Kita, T. Distinct signaling pathways for MCP-1-dependent integrin activation and chemotaxis. J. Biol. Chem., 2001, 276, 16555-16560.
146. Nagata, Y.; Lan, K. H.; Zhou, X.; Tan, M.; Esteva, F. J.; Sahin, A. A.; Klos, K. S.; Li, P.; Monia, B. P.; Nguyen, N. T.; Hortobagyi, G. N.; Hung, M. C.; Yu, D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell, 2004, 6, 117-127. (Pubitemid 39485684)
147. Tabellini, G.; Tazzari, P. L.; Bortul, R.; Billi, A. M.; Conte, R.; Manzoli, L.; Cocco, L.; Martelli, A. M. Novel 2'-substituted, 3'-deoxy-phosphatidyl-myoinositol analogues reduce drug resistance in human leukaemia cell lines with an activated phosphoinositide 3-kinase/AKT pathway. Br. J. Haematol., 2004, 126, 574-582. (Pubitemid 39093101)
148. Principe, P.; Braquet, P. Advances in either phospholipids treatment of cancer. Crit. Rev. Oncol. Hematol., 1995, 18, 155-178.
149. Vink, S. R.; Schellens, J. H.; Beijnen, J. H.; Sindermann, H.; Engel, J.; Dubbelman, R.; Moppi, G.; Hillebrand, M. J.; Bartelink, H.; Verheij, M. Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours. Radiother. Oncol., 2006, 80, 207-213. (Pubitemid 44314020)